BofA: AI Sector Positioning Overcrowded, Room for Alpha Narrows
nashnova research
BofA's latest active-manager positioning report warns that the "buy AI capex, sell consumer" trade is near capacity — generating alpha from this consensus is getting harder, and capital may need a new destination.
How crowded is the "buy AI, sell consumer" trade?
BofA's data on active-fund sector exposure shows industrials vs. consumer discretionary positioning is near an all-time high.
Meanwhile, IT services, consumer finance, and software — sectors tagged as "AI disruption victims" — sit at near-record lows.
This means → almost every active manager is on the same side of the boat. When positioning is this one-directional, the marginal alpha from the same trade shrinks toward zero.
Where do large-cap tech stocks stand now?
BofA holds an overall neutral view on tech/media/telecom (TMT), arguing that risk and reward for large-cap tech are now more fairly priced in.
Apple and Microsoft remain "stable core holdings" — owned by over 80% of funds — but are actually slightly underweight because their benchmark weight is so large.
In plain terms = nearly every fund owns Apple and Microsoft, yet they still can't match the index weight of these two stocks. That's not bearishness — it's "too big to fully match."
How much dry powder do managers have left?
Active funds' non-S&P 500 exposure has dropped near a historic low of roughly 15%; it touched 14% in 2024, versus 20% in 2020.
Cash levels have stayed low since 2024. ADR holdings sit at about 2%, essentially unchanged in recent years.
This means → managers have nearly all their capital parked in S&P 500 names, with little cash on hand. If a new opportunity emerges, room to maneuver is tight.
Why is healthcare back on the radar?
BofA notes rising client interest in "growth names unrelated to AI." Healthcare companies are re-entering fund managers' field of view.
The bank sees healthcare as offering idiosyncratic alpha — stock-specific drivers rather than broad-market beta — plus tailwinds from aging demographics and AI applications in medicine.
Only about 10% of funds are overweight healthcare today, versus nearly 20% around 2015 and 2019. This reflects relatively low crowding and limited potential selling pressure.
What about policy risk and tax-loss selling?
The key constraint on healthcare is policy risk, especially ahead of U.S. midterm elections, where regulatory shifts could hit sector valuations.
A separate short-term headwind: tax-loss selling. BofA screens for S&P 500 stocks down at least 10% year-to-date and broadly overweight — these names went on to drop another ~6 percentage points on average.
BofA believes the selling pressure may not be over: institutions did not sell aggressively last month, and this strategy's returns are typically worst in October. In plain terms = the historical playbook says "sell now, buy back no earlier than November."
Which names are the most crowded — and the most ignored?
Most crowded (heavily overweight): Meta, Starbucks, Philip Morris, ConocoPhillips, Charles Schwab, Vertex, Boeing, Broadcom, Corteva, Welltower, Constellation Energy.
Most ignored (well below benchmark): News Corp-B, Hasbro, Hormel Foods, Texas Pacific Land, Erie Indemnity, Hanes Brands, Generac, Trimble, Amcor, KinderMorgan, Eversource Energy.
This means → crowded names face concentrated selling risk if the consensus cracks. Ignored names, if fundamentals improve, carry alpha potential from the expectations gap.
市场有风险，内容仅供研究参考，不构成投资建议。